-
Electronic (PDF)
-
Site License
-
Enterprisewide
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, November 2011, Pages: 102
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), were approved in the US. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the US despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.
Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but is significantly higher in Japan (18.4%). This disparity across geographical markets exists because of the variation in the approval dates for some of the drugs in the US, Europe and Japan. In the US, therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved, whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, and its acceptance across Europe is predicted to represent a growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have a similar mode of action to that of existing drugs, and are therefore unlikely to impact the market significantly.
During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the decline in the market valuations due to patent expiries of these drugs is likely to be compensated by the new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will register growth through 2010 to 2018.
Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitors, selective alpha2A-adrenergic receptor agonists, serotonin-norepinephrine-dopamine reuptake inhibitors, selective serotonin (5-HT1)-dopamine antagonists, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitors (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonists, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonists, alpha7 NNR agonists, serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonists, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonists, histamine H3 receptor antagonists, selective alpha2A-adrenergic receptor agonists, histamine H3 autoreceptor antagonists, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitors, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonists.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
1
1
1.1 List of Tables
1.2 List of Figures
2 Attention Deficit Hyperactivity Disorder (ADHD) - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Prevalence/Incidence
2.2.2 Quality of Life (Qol)
2.2.3 Pharmacoeconomic Burden:
2.3 Etiology and Pathophysiology
2.3.1 Genetic Causes
2.3.2 Environmental Causes
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Diagnostic Criteria for ADHD
2.5.2 Rating Scales Used for the Diagnosis:
2.6 Treatment and Management Options
2.6.1 Pharmacologic Treatment:
2.6.2 Behavioral therapy
2.7 Referral Pathway
2.8 GlobalData, Pipeline Report Guidance
3 ADHD Therapeutics - Market Characterization
3.1 ADHD Therapeutics Market Size (2005–2010) – Global
3.2 ADHD Therapeutics Market Forecast (2010–2018) – Global
3.3 ADHD Therapeutics Market Size (2005–2010) – The US
3.4 ADHD Therapeutics Market Forecast (2010–2018) – The US
3.5 ADHD Therapeutics Market Size (2005–2010) – France
3.6 ADHD Therapeutics Market Forecast (2010–2018) – France
3.7 ADHD Therapeutics Market Size (2005–2010) – Germany
3.8 ADHD Therapeutics Market Forecast (2010–2018) – Germany
3.9 ADHD Therapeutics Market Size (2005–2010) – Italy
3.10 ADHD Therapeutics Market Forecast (2010–2018) – Italy
3.11 ADHD Therapeutics Market Size (2005–2010) – Spain
3.12 ADHD Therapeutics Market Forecast (2010–2018) – Spain
3.13 ADHD Therapeutics Market Size (2005–2010) – The UK
3.14 ADHD Therapeutics Market Forecast (2010–2018) – The UK
3.15 ADHD Therapeutics Market Size (2005–2010) – Japan
3.16 ADHD Therapeutics Market Forecast (2010–2018) – Japan
3.17 Drivers and Barriers for the ADHD Therapeutics Market
3.17.1 Drivers for the ADHD Therapeutics Market
3.17.2 Barriers for the ADHD Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 ADHD Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the ADHD Therapeutics Market
4.3.1 Ritalin LA (methylphenidate hydrochloride long acting capsules)
4.3.2 Adderall XR (Mixed amphetamine salt)
4.3.3 Daytrana (methylphenidate transdermal system)
4.3.4 Vyvanse (lisdexamfetamine dimesylate)
4.3.5 Concerta (methylphenidate hydrochloride)
4.3.6 Strattera (atomoxetine hydrochloride)
4.3.7 Intuniv (guanfacine)
4.3.8 Kapvay (clonidine hydrochloride)
4.4 Key Takeaway
5 ADHD Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 ADHD Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 ADHD Therapeutics – Filed Pipeline
5.3.2 ADHD Therapeutics – Phase III Pipeline
5.3.3 ADHD Therapeutics – Phase II/III Pipeline
5.3.4 ADHD Therapeutics – Phase II Pipeline
5.3.5 ADHD Therapeutics – Phase I Pipeline
5.3.6 ADHD Therapeutics – Pre-Clinical Pipeline
5.3.7 Technology Trends Analytic Framework
5.4 ADHD Therapeutics Market –Clinical Pipeline by Mechanism of Action
5.5 ADHD Therapeutics – Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drug Under Clinical Development
5.6.1 NWP06
5.6.2 CM-4612
5.6.3 RIT124D
5.6.4 JNS001
5.7 Key Takeaway
6 ADHD Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in ADHD Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 ADHD Therapeutics: Implications for Future Market Competition
8 ADHD Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Curemark, LLC.
8.2.2 Johnson & Johnson
8.2.3 NextWave Pharmaceuticals
8.2.4 Novartis AG
8.2.5 Shire Plc.
8.2.6 Other Companies in the ADHD Therapeutics Market
9 ADHD Therapeutics - Licensing and Partnership Deals
10 ADHD Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: ADHD Therapeutics- Comorbidities
Table 2: Prevalence of subtypes of ADHD as per KiGGS
Table 3: Common Assessment Scales used to aid the diagnosis of ADHD
Table 4: Rating Scales used for the diagnosis of childhood, adolescent and adult ADHD
Table 5: Drugs commonly prescribed for ADHD
Table 6: ADHD Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 7: ADHD Therapeutics Market, Global, Forecasts ($m), 2010–2018
Table 8: ADHD Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 9: ADHD Therapeutics Market, The US, Forecasts ($m), 2010–2018
Table 10: ADHD Therapeutics Market, France, Revenue ($m), 2005–2010
Table 11: ADHD Therapeutics Market, France, Forecasts ($m), 2010–2018
Table 12: ADHD Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 13: ADHD Therapeutics Market, Germany, Forecasts ($m), 2010–2018
Table 14: ADHD Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 15: ADHD Therapeutics Market, Italy, Forecasts ($m), 2010–2018
Table 16: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 17: ADHD Therapeutics Market, Spain, Forecasts ($m), 2010–2018
Table 18: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 19: ADHD Therapeutics Market, The UK, Forecasts ($m), 2010–2018
Table 20: ADHD Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 21: ADHD Therapeutics Market, Japan, Forecasts ($m), 2010–2018
Table 22: Adverse Events Associated with Adderall XR
Table 23: Clinical Studies for Adderall XR
Table 24: Adverse Events Associate with Daytrana
Table 25: Clinical Studies for Daytrana
Table 26: ADHD Therapeutics- Adverse Events Associated with Vyvanse
Table 27: Clinical Studies for Vyvanse
Table 28: Common Treatment Emergent Adverse Events Associated with Concerta
Table 29: Clinical Studies for Concerta
Table 30: Common Treatment Emergent Adverse Events Associated with Strattera
Table 31: Clinical Studies for Strattera
Table 32: Common treatment Emergent Adverse Events Associated with Intuniv
Table 33: Clinical Studies for Intuniv
Table 34: Common Adverse Events Associated with Kapvay in Children and Adolescents
Table 35: Clinical Studies for Kapvay
Table 36: ADHD Therapeutics, Filed Pipeline, 2011
Table 37: ADHD Therapeutics, Phase III Pipeline, 2011
Table 38: ADHD Therapeutics, Phase II/III Pipeline, 2011
Table 39: ADHD Therapeutics, Phase II Pipeline, 2011
Table 40: ADHD Therapeutics, Phase I Pipeline, 2011
Table 41: ADHD Therapeutics, Pre-Clinical Pipeline, 2011
Table 42: ADHD Therapeutics, Most Promising Drugs Under Clinical Development, 2011
Table 43: ADHD Therapeutics, Clinical Trials by Country, 2011
Table 44: ADHD Therapeutics - Clinical Trials by Phase, 2011
Table 45: ADHD Therapeutics, Clinical Trials by Status (%), 2011
Table 46: ADHD Therapeutics, Prominent Sponsors, 2011
Table 47: ADHD Therapeutics, Top Companies Participating in Clinical Trials, 2011
Table 48: Curemark LLC., ADHD Pipeline, 2011
Table 49: Curemark LLC., CNS Pipeline, 2011
Table 50: Johnson & Johnson, ADHD Pipeline, 2011
Table 51: Johnson & Johnson, CNS Pipeline, 2011
Table 52: NextWave Pharmaceuticals, ADHD Pipeline, 2011
Table 53: NextWave Pharmaceuticals, CNS Pipeline, 2011
Table 54: Novartis ADHD Pipeline, 2011
Table 55: Novartis, CNS Pipeline, 2011
Table 56: Shire Plc., ADHD Pipeline, 2011
Table 57: Shire Plc., CNS Pipeline, 2011
Table 58: ADHD Therapeutics Market, Future Players
Table 59: ADHD Therapeutics, Global, Deals, 2009-2011
1.2 List of Figures
Figure 1: Co-existing Conditions in ADHD
Figure 2: A Three-Dimensional, High-Resolution MRI Image of the Brain of A Patient with ADHD
Figure 3: ADHD Therapeutics- Symptoms
Figure 4: ADHD Therapeutics – Diagnosis Of ADHD
Figure 5: ADHD Therapeutics – Barkley Home Situations Questionnaire (HSQ)
Figure 6: ADHD Therapeutics - Adult Self Report Scale VI.I (ASRS-VI.I) Screener
Figure 7: ADHD Therapeutics - Referral Pathway
Figure 8: ADHD Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 9: ADHD Therapeutics Market, Global, Forecast ($m), 2010–2018
Figure 10: ADHD Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 11: ADHD Therapeutics Market, The US, Forecast ($m), 2010–2018
Figure 12: ADHD Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 13: ADHD Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 14: ADHD Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 15: ADHD Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 16: ADHD Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 17: ADHD Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 18: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 19: ADHD Therapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 20: ADHD Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 21: ADHD Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 22: ADHD Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 23: ADHD Therapeutics Market, Japan, Forecast ($m), 2010–2018
Figure 24: Opportunity and Unmet Need in the ADHD Therapeutics Market, 2010
Figure 25: ADHD Therapeutics, Strategic Competitor Assessment, 2010
Figure 26: ADHD Therapeutics – Pipeline by Phase of Development, 2011
Figure 27: ADHD Therapeutics, Technology Trends Analytics Framework, 2011
Figure 28: ADHD Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 29: ADHD Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 30: ADHD Therapeutics - Clinical Trials by Country, 2011
Figure 31: ADHD Therapeutics, Clinical Trials by Phase (%), 2011
Figure 32: ADHD Therapeutics, Clinical Trials by Status (%), 2011
Figure 33: ADHD Therapeutics, Overall sponsors (%), 2011
Figure 34: ADHD Therapeutics, Prominent Sponsors (%), 2011
Figure 35: ADHD Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 36: ADHD Therapeutics Market, Drivers and Restraints, 2011
Figure 37: Implications for Future Market Competition in the ADHD Market, 2011
Figure 38: ADHD Therapeutics Market, Pipeline by Company, 2011
Figure 39: GlobalData, Market Forecasting Model
GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market. The report identifies the key trends shaping and driving the global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
ADHD Therapeutics Market is Forecast to Show Steady Growth Until 2018
GlobalData estimates that the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), were approved in the US. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the US despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.
Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but is significantly higher in Japan (18.4%). This disparity across geographical markets exists because of the variation in the approval dates for some of the drugs in the US, Europe and Japan. In the US, therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved, whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, and its acceptance across Europe is predicted to represent a growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have a similar mode of action to that of existing drugs, and are therefore unlikely to impact the market significantly.
Curemark, LLC.
Johnson & Johnson
NextWave Pharmaceuticals
Novartis AG
Shire Plc.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
